News

Healio2d
Finerenone plus SGLT2 inhibitor reduces albuminuria more than either drug alone
Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...
Medscape3d
Combination Therapy Offers CONFIDENCE to CKD+T2D Patients
Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...
MedPage Today3d
Picking the Right Osteoanabolic Agent First, and What Comes Next
An osteoanabolic agent should be the first choice treatment for patients at high or imminent risk for fracture, but once ...
MedPage Today on MSN4d
Two Drugs Better Than One for Easing Albuminuria in CKD Patients With Diabetes
An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary ...
FDA approves a first-of-its-kind eye implant that slows vision loss in rare eye disease
For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have ...
ascopubs.org6d
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small ...
Pharmacokinetic analysis showed that the CSF to free plasma osimertinib ratio was 22%. Most safety profiles were grade 1 and 2. Treatment with 80 mg once daily osimertinib achieved a median OS of 15.0 ...